Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
Takeda Pharmaceuticals North America Inc. in April will begin selling a new pill to treat high blood pressure after the Food and Drug Administration approved the Deerfield-based company’s Edarbi tablets, the agency said.
Edarbi, which will cost about $75 for a month’s supply, enters a crowded field of blood pressure medications, including several cheaper generics that employers and consumer groups say work well and can cost pennies a day. Get the full story »
Baxter International Inc. said it has expanded a deal with Japan’s largest drug maker to bring its cell-based vaccine technology to that country.
The Deerfield-based medical product giant said terms of the agreement with Osaka, Japan-based Takeda Pharmaceutical Company Limited call for “Takeda and Baxter will expand upon their previously announced collaboration to bring Vero cell culture-based influenza vaccines to the Japanese market.” Get the full story »
The Food and Drug Administration said Friday that it has started a safety review of Takeda Pharmaceutical Co.’s diabetes drug Actos looking at links to bladder cancer.
The FDA said the review was prompted from preliminary, five-year data from an ongoing study involving the drug. The study, designed to follow patients for 10-years, is being funded by Takeda. Get the full story »
FDA scientists debated how to interpret the outcome of a large clinical trial that GlaxoSmithKline PLC says backs the safety of its diabetes drug Avandia.
Avandia is currently being reviewed by a federal panel that is scheduled to vote Wednesday on whether it thinks Avandia should remain on the U.S. market. FDA Commissioner Margaret Hamburg opened the meeting Tuesday, telling advisers to “follow the science where ever it may lead and the rest will fall into place.” Get the full story »
Pharmaceutical Research and Manufacturers of America, which includes Abbott Laboratories and Takeda Pharmaceuticals as members, said Tuesday that John Castellani will become the drug lobby’s president and chief executive, effective Sept. 1.
Castellani, who replaces the retiring Billy Tauzin, comes to PhRMA after nearly a decade as president and CEO of Business Roundtable, an association of corporate executives. Get the full story »
